[Thiamphenicol glycinate acetylcysteinate in the treatment of acute respiratory infections with mucostasis].
Thiamphenicol glycinate acetylcysteinate (TGA), a molecular combination of an antibiotic and a mucolytic, is particularly indicated in the treatment of acute bronchopulmonary infections characterized by mucostasis. Our report is a synthesis of 9 clinical studies on TGA made in France between 1972 and 1976. These studies involved a total of 587 patients (475 adults and 112 children) with bacterial bronchopulmonary infections. Most of the patients were hospitalized, and none were affected by abnormal renal function or hematologic disorders. All received TGA per os or i.m. for an average of 7 days. The effects of TGA were evaluated clinically, radiologically, biologically and bacteriologically. The results of TGA treatment were assessed: - Favourable in 337 patients (58%), TGA mucolytic and antibiotic activity rapidly producing complete cures; - Useful in 160 patients (27%), TGA mucolytic and antibiotic activity producing slow cures; - Nil in 90 patients (15%), TGA producing no evidence of mucolytic and antibiotic activity. During treatment, various minor side effects were observed. In the case of two patients, treatment was not tolerated and therefore suspended. At the end of treatment, hypereosinophilia was observed in 5 patients and thrombocytopenia, anemia or inverted W.B.C. differential counts were observed in 22 patients, due to the presence of thiamphenicol glycinate in the molecule. These effects proved spontaneously reversible.
D000111:Acetylcysteine / Q000009:adverse effects / Q000627:therapeutic use*; D000208:Acute Disease; D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D004338:Drug Combinations / Q000009:adverse effects / Q000627:therapeutic use; D005100:Expectorants / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009093:Mucus / Q000378:metabolism; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000503:physiopathology; D013839:Thiamphenicol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D005100:Expectorants; C028814:thiamphenicol glycinate acetylcysteinate; D013839:Thiamphenicol; D000111:Acetylcysteine
L'acétylcystéinate de thiamphénicol glycinate dans le traitement des infections respiratoires aiguës avec mucostase.